Latest Commercialization News

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Spacetalk Ltd has signed a non-binding MOU with Vodafone Australia to distribute its Family Safety software platform, marking a strategic shift towards a software-led business model and aiming for significant recurring revenue growth.

SKS Technologies Group has reported a robust half-year performance, driven by a landmark $130 million data centre contract and a strategic acquisition, positioning it strongly for FY26 growth.

Abacus Group has reported a strong turnaround with a $47.6 million net profit for the half-year to December 2025, maintaining steady funds from operations and declaring a consistent interim distribution. The group is also exploring internalising management of its key joint venture, Abacus Storage King.

Calix Limited reported a solid 21% revenue increase for the half-year ending December 2025, but losses ballooned by 250%, raising questions about the path to profitability.

Nanosonics Limited reported a 9% revenue increase in the first half of FY26, driven by a growing installed base and recurring sales, while advancing the commercial rollout of its new CORIS endoscope reprocessing system.

Alicanto Minerals is launching an extensive 50,000-metre drilling campaign at its newly acquired Mt Henry Gold Project in Western Australia, aiming to expand and upgrade its existing 0.9 million ounce gold resource.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.

Nickel Industries reported a reduced loss after tax of $41.2 million for 2025, underpinned by steady production and strategic progress on its ENC HPAL project and sustainability initiatives.

TMK Energy Limited reveals strong pilot well results and a robust phased development plan for its Gurvantes XXXV Coal Seam Gas project in Mongolia, underpinned by independently certified resources and strategic partnerships.